Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

, hereditary angioedema (HAE), and allergic rhinitis care. Palforzia's discontinuation closed the chapter on the first FDA-approved peanut oral immunotherapy (OIT), while new omalizumab (Xolair) data reinforced a biologic alternative for multifood allergy.

 — FDA approves seasonal allergic rhinitis treatment for children ages 6–11

— FDA-approved peanut allergy oral immunotherapy discontinued July 31, 2026

— FDA accepts NDA for oral hereditary angioedema (HAE) attack treatment

 — Anaphylaxis guidelines still lag behind needle-free option

In HAE, sebetralstat (Ekterly) quality-of-life data and Pharvaris' deucrictibant NDA acceptance signaled a fast-maturing oral treatment landscape. Meanwhile, epinephrine nasal spray (neffy) guidance and an expanded Ryaltris (olopatadine/mometasone) pediatric indication rounded out a busy month for practicing allergists. Here are 6 allergy headlines you may have missed.

New FDA-Approved Option for Pediatric Allergic Rhinitis

FDA Approves Ryaltris for Children Aged 6 to 11 With Seasonal Allergic Rhinitis

The FDA expanded Ryaltris (olopatadine hydrochloride/mometasone furoate, Glenmark Pharmaceuticals) to children aged 6 to 11 years with seasonal allergic rhinitis, extending the fixed-dose nasal spray beyond its original 2022 approval for patients aged ≥ 12 years. The expansion was supported by a phase 3 trial of 446 pediatric patients showing significant nasal symptom improvement over 14 days of twice-daily dosing versus placebo. Marc Kikuchi, president and business head, North America, at Glenmark Pharmaceuticals, called the approval a step toward broader pediatric access to combination antihistamine-corticosteroid nasal therapy.

The Post-Palforzia Food Allergy Treatment Landscape

Palforzia Discontinued, Ending the Only FDA-Approved Peanut OIT Option

Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp), the only FDA-approved peanut OIT, was permanently discontinued as of July 31, 2026, per manufacturer Stallergenes Greer. Approved in 2020 and originally developed by Aimmune before passing through Nestlé Health Science, Palforzia's exit leaves clinicians without an FDA-sanctioned OIT option for peanut allergy. Allergists Robert Wood, MD (Johns Hopkins), and Jacqueline Ross, MD (Allergy Partners of New Jersey), discussed what the loss means for patients currently in treatment and how practices should manage the transition, including counseling families on non-FDA-approved OIT protocols and biologic alternatives moving forward.

Omalizumab Outperforms Oral Immunotherapy for Multifood Allergy

New OUTMATCH stage 2 trial data across 10 US academic centers showed omalizumab (Xolair) outperforming multiallergen OIT (MOIT) in patients with multifood allergy, addressing a gap left by the absence of prior head-to-head randomized comparisons. Trial investigator Robert A. Wood, MD (Johns Hopkins), reported a markedly low dropout rate among patients treated with the biologic. Omalizumab, FDA-approved in 2024 for reducing allergic reactions following accidental food exposure, now stands as 1 of only 2 approved food allergy therapies, alongside Palforzia, which exited the market this same month.

Age, Maintenance Dosing Shape MOIT Counseling in Multifood Allergy

Hereditary Angioedema's Oral Treatment Pipeline Widens

FDA Accepts NDA for Oral Deucrictibant for HAE Attacks

The FDA accepted Pharvaris' New Drug Application for deucrictibant immediate-release capsules, an oral bradykinin B2 receptor antagonist for on-demand HAE attack treatment, setting an April 23, 2027, PDUFA date. Phase 3 RAPIDe-3 data, drawn from > 1300 treated attacks, met its primary endpoint and all 11 secondary efficacy endpoints, with a median 1.28 hours to symptom relief onset. If approved, deucrictibant IR would become the first oral B2-antagonist option for acute HAE attacks, joining sebetralstat as an oral on-demand alternative to injectable therapies.

Sebetralstat Shows QoL Gains in HAE Patients on Prophylaxis

New KONFIDENT-S open-label extension data showed sebetralstat (Ekterly, KalVista Pharmaceuticals) delivered meaningful quality-of-life gains for patients with HAE already stable on long-term prophylaxis with berotralstat, lanadelumab, or C1 inhibitor replacement. Investigator Daniel Soteres, MD (Asthma & Allergy Associates), reported a 10.3-point improvement in Angioedema Quality of Life Instrument scores among 34 participants, with the largest gains in fatigue/mood, fears/shame, and functioning domains. Treatment satisfaction was high, with 88.8% of sebetralstat-treated attacks rated satisfactory, reinforcing oral on-demand therapy's role even in well-controlled patients.

Anaphylaxis Guidelines Still Catching Up to Needle-Free Epinephrine

Epinephrine Nasal Spray Available, but Anaphylaxis Guidelines Lag

Epinephrine nasal spray (neffy, ARS Pharmaceuticals) remains ahead of formal anaphylaxis practice parameters nearly 2 years after its initial approval. David Golden, MD (Johns Hopkins), co-chair of the 2023 anaphylaxis guideline update, told 

that "guidelines don't happen overnight," leaving clinicians to interpret real-world use of the needle-free option without updated society recommendations. The gap highlights a common lag between novel drug approvals and formal guideline incorporation.

Articles

Seasonal allergic rhinitis care expanded with FDA approval of Ryaltris for ages 6–11 based on phase 3 symptom reduction over 14 days. Food allergy management shifted as Palforzia was permanently discontinued, eliminating the only FDA-approved peanut OIT, while OUTMATCH stage 2 data supported omalizumab over multiallergen OIT with low discontinuation. Hereditary angioedema continued moving oral: deucrictibant NDA acceptance advanced a potential first oral B2 antagonist for acute attacks, and sebetralstat improved quality-of-life despite prophylaxis. Needle-free epinephrine via neffy remains ahead of updated anaphylaxis guidelines.

FDA expands Ryaltris to younger children with seasonal allergic rhinitis, Palforzia discontinues, and HAE's oral pipeline widens with deucrictibant and sebetralstat.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

6 Allergy Headlines You Missed in July 2026

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

After a quiet June, cardiology came roaring back for a full slate in July 2026. The US Food and Drug Administration produced a slew of approvals for key devices and medications in dyslipidemia and heart failure (HF), while the SYMPHONY-PE trial demonstrated the value of early mechanical thrombectomy in improving cardiovascular health without impacting safety in patients with pulmonary embolism. Additionally, the American Heart Association (AHA) and the American College of Cardiology (ACC) released the first-ever clinical treatment guidelines for cardiovascular-kidney-metabolic (CKM) syndrome, paving a way forward for the treatment of this prolific condition.

As July 2026 draws to a close, the editorial team at 

 has collected 6 of the most impactful must-know headlines for the past 31 days. Get up to speed on anything that may have slipped through the cracks for you below:


FDA Approves Enlicitide for LDL-C Lowering in Adults With Hypercholesterolemia


On July 16, 2026, the FDA announced its approval of enlicitide 20 mg tablets under the brand name Lipfendra for LDL-C lowering in adults with hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH). The decision was supported by the CORALreef Lipids and CORALreef HeFH trials, which both demonstrated substantial reductions in LDL-C, non-HDL-C, and ApoB compared to increases with placebo.


FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD


MannKind’s Furoscix ReadyFlow, a full 80 mg/dL dose of subcutaneous furosemide delivered via an autoinjector in <10 seconds, was approved by the FDA on July 24, 2026. The basis for the approval, a collection of clinical data demonstrating furosemide’s efficacy, optimal bioavailability, and positive tolerability and safety, also demonstrated equivalent urine output, sodium excretion, and potassium secretion at 6, 8, and 12 hours versus intravenous furosemide.


CaRi-Heart Receives FDA De Novo Authorization for Coronary Inflammation


The FDA granted De Novo authorization to the CaRi-Heart device to quantify coronary inflammation from routine coronary CT angiography (CCTA) on July 29, 2026. The device applies AI analysis to CCTA images, searching for inflammation-related changes in the fat surrounding the coronary arteries. The device then quantifies these changes as the fat attenuation index score, a proprietary biomarker of coronary inflammation, and generates the CaRi-Heart Risk score, an estimation of a patient’s 10-year cardiovascular mortality risk. Parent company Caristo plans to launch CaRi-Heart commercially in the US during Q3 2026 and will expand availability through the end of the year.


AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT


A new analysis of the AXIOMATIC-TKR trial highlighted milvexian’s capacity for inhibiting intrinsic pathway thrombin generation (TG) without impacting extrinsic pathway TG, effectively decoupling thrombosis from hemostasis in patients with deep-vein thrombosis (DVT). The trial demonstrated that milvexian successfully reduced venous thromboembolism in patients undergoing an elective unilateral total knee arthroplasty.


SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes


The SYMPHONY-PE trial, a prospective, multicenter, single-arm interventional study evaluating the Symphony Thrombectomy System from Imperative Care in patients with acute, intermediate-risk pulmonary embolism (PE), has demonstrated the safety of early mechanical thrombectomy compared to late thrombectomy. The earlier the intervention, the trial suggests, the greater the cardiovascular improvement, without a substantial effect on safety event rates.


AHA, ACC Release First-Ever Cardiovascular-Kidney-Metabolic Syndrome Guidelines


The newly released guidelines for CKM Syndrome from the AHA and ACC fully replace the 2013 Guideline for the Management of Overweight and Obesity, recommending a complete overhaul in how the prolific disease is managed. CKM syndrome staging is now recommended in all adolescents and adults to prevent progression and reduce cardiovascular events, while the PREVENT equations have once more taken center stage as the tool to evaluate atherosclerotic cardiovascular disease (ASCVD), HF, and total cardiovascular disease risk. Additionally, the guidelines emphasize the need for interdisciplinary care, treatment for overweight or obesity, and assessment of potential chronic kidney disease.

July 2026 featured multiple FDA actions and clinically relevant readouts across dyslipidemia, heart failure, thrombosis, and imaging. Enlicitide was cleared for LDL-C lowering in hypercholesterolemia and HeFH based on CORALreef programs demonstrating reductions in LDL-C, non-HDL-C, and ApoB. Subcutaneous furosemide via an autoinjector gained approval for edema in HF and CKD with diuretic effects comparable to IV dosing. An AI-enabled CCTA tool received De Novo authorization to quantify coronary inflammation and estimate 10-year mortality risk. New data supported early PE thrombectomy and intrinsic-pathway anticoagulation strategies, alongside inaugural AHA/ACC CKM syndrome guidelines.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Structural Heart Disease

Videos

6 Cardiology Headlines You Missed in July 2026

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Patients with significant baseline disease reached high efficacy benchmarks by week 8 on tapinarof cream.

Tapinarof offers a non-steroidal option usable on all body surface areas, simplifying treatment regimens.

Unmet needs remain for patients younger than 2 years, an area for future study.

 from the ADORING 1 and ADORING 2 phase 3 trials continue to reinforce tapinarof cream, 1% (VTAMA) as a treatment option for 

 across a broad range of patients, according to Linda Stein Gold, MD.

 interview, Stein Gold, known for her role as director of Dermatology Clinical Research and division head of Dermatology at Henry Ford Health, Stein Gold highlighted some of the implications of her team’s findings on tapinarof cream 1%.

What EASI 75, vIGA-AD Scores Reveal About Tapinarof's Eczema Efficacy

What Do EASI 75 and vIGA-AD Scores Reveal About Treatment Response?

Stein Gold noted that regulatory benchmarks for treatment success have grown considerably more stringent over the course of her career. She explained that current 

 standards for clear or almost-clear skin, as measured by vIGA-AD, represent a high bar, while EASI 75 reflects a 75% improvement from baseline.

Given that most trial participants had disease severe enough to be candidates for systemic therapy, she said achieving these benchmarks with a once-daily, non-steroidal topical cream by week 8 represents a meaningful clinical result.

How Could These Findings Influence Atopic Dermatitis Management Across Age Groups?

Stein Gold said clinicians have long relied on topical steroids as a short-term mainstay of atopic dermatitis therapy, despite the chronic nature of the disease. She emphasized the value of non-steroidal options that can be applied across multiple body surface areas, including the face, skin folds, and hands, to simplify treatment regimens and support longer-term disease control.

What Unmet Needs Remain in Pediatric Atopic Dermatitis?

Looking ahead, Stein Gold pointed to tapinarof's expanding role across chronic inflammatory skin diseases, noting its existing approval down to age 2 in atopic dermatitis and its FDA approval in psoriasis. She anticipates non-steroidal options will increasingly limit steroid use in clinical practice.

However, she identified younger pediatric patients, including infants as young as 3 to 4 months, as a population in need of further study, calling it a key unmet need in atopic dermatitis care.

Disclosures for Stein Gold include AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults. Organon. July 24, 2026. Accessed July 31, 2026. 

https://www.organon.com/news/new-analysis-of-phase-3-pooled-data-for-organons-vtama-tapinarof-cream-1-demonstrates-early-consistent-improvements-in-atopic-dermatitis-patients-across-pediatric-age-groups-and-in/

Fonacier L, Boguniewicz M, Ohayon J, et al. Tapinarof cream 1% in atopic dermatitis: consistent efficacy across age groups from pooled ADORING trials. Poster presented at: Society for Pediatric Dermatology (SPD) Annual Meeting; July 23, 2026; Minneapolis, MN.

Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Claudia Nau, PhD | Image Credit: Kaiser Permanente Research

Medically tailored grocery deliveries may aid adults with 

 and Medicaid insurance in managing their blood sugar, according to recent research from Kaiser Permanente.

Although Food is Medicine programs are widely considered a promising approach for addressing food insecurity and chronic conditions associated with nutrition, few studies have effectively examined their direct impact on patients, particularly those with public health insurance. To this end, Kaiser Permanente conducted the present study to determine whether these interventions have calculable impacts on patient health and nutrition.

“This trial shows that food-based support can help patients with low incomes lower their blood sugar levels above and beyond the health care they receive,” Claudia Nau, PhD, a researcher with Kaiser Permanente Southern California Department of Research and Evaluation and lead author of the study, said in a statement. “Our findings suggest that addressing access to healthy food can play a meaningful role in diabetes care for patients, particularly those facing economic and social barriers.”

Nau and colleagues conducted a randomized controlled trial within Kaiser Permanente Southern California, examining whether medically tailored grocery deliveries improved blood sugar control among adults with T2D. Patients were eligible if they had been diagnosed with T2D for ≥24 months, had ≥2 HbA1cs of ≥7.5% in 12 months before recruitment, and had Medicaid insurance at the last HbA1c test.

Patients were randomly assigned to receive either usual care or 1 of 2 monthly amounts of medically tailored groceries paired with support. These 2 groups included weekly home deliveries of healthy foods scaled to household size and access to phone-based nutrition counseling. Patients in all 3 arms were assigned to complete 3 questionnaires during the trial – in the 2 intervention arms, patients’ HbA1cs were collected at the end of the trial.

The study’s primary outcome was change in HbA1c from baseline to 6 months. Secondary endpoints included the difference in patient-reported food security between the intervention groups and the control group, the difference in patient-reported food-related self-management between the 3 groups, and the difference in patient-reported diet quality between the 3 groups, among others.

A total of 460 Medicaid-insured patients were enrolled in the trial, all of whom had persistently elevated blood sugar levels and were receiving care at 1 of 12 medical office buildings across Southern California. Patients were recruited between November 2021 and July 2022 and were followed for a total of 6 months. Investigators contrasted changes in blood sugar and food-related outcomes using both electronic health records and participant surveys.

Ultimately, patients who received medically tailored groceries saw greater improvements in blood sugar than those assigned to usual care – this was reflected in an additional 0.4 point reduction in HbA1c over 6 months. Patients receiving groceries also saw an almost 215% increase in the odds of food security and a 365% increase in the odds of nutrition security. Additionally, blood sugar improvements were consistent whether patients received the higher or lower level of medically-tailored groceries.

“These trial results further demonstrate that healthy food can be a powerful tool in treatment and management of chronic disease,” Dariush Mozaffarian, MD, director of the Food is Medicine Institute at the Friedman School at Tufts University, said in a statement. “Incorporating Food is Medicine programs, like medically tailored groceries, into Medicaid benefits recognizes nutrition as a fundamental component of health and can lead to better patient outcomes.”

Kaiser Permanente. Home-delivered, medically tailored groceries improve diabetes control. 

https://www.eurekalert.org/news-releases/1136616

Kaiser Permanente. Food as Medicine Study. ClinicalTrials.gov Identifier: NCT05407376. Updated March 24, 2025. Accessed July 31, 2026. 

https://clinicaltrials.gov/study/NCT05407376

A randomized controlled trial in Kaiser Permanente Southern California evaluated medically tailored grocery deliveries plus phone-based nutrition counseling for Medicaid-insured adults with long-standing T2D and persistently elevated HbA1c. Over 6 months, participants receiving tailored groceries achieved an additional 0.4% absolute HbA1c reduction versus usual care. The intervention substantially increased patient-reported food security and nutrition security, with benefits observed across both higher and lower grocery allotments. Findings support nutrition-access interventions as additive to standard clinical management in economically constrained populations.

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D

Donya Shahamati, MS | Image Credit: LinkedIn

The Planetary Health Diet is associated with a lower risk of overall cardiovascular disease, 

 among postmenopausal women, according to the results of a 20-year study.

The Planetary Health Diet, created by the EAT-

 Commission in 2026, is designed to optimize human health without sacrificing the earth’s environment. The diet is structured with an expected future population of 10 billion people – to protect land and nutrition access, the diet is flexible and sustainable, focusing on whole plant foods, healthy fats, and very low amounts of animal products.

“Our results suggest that people may not need to follow a perfect or very restrictive diet to see potential heart-health benefits,” Donya Shahamati, MS, a doctoral student in public health at the University of California, Irvine, said in a statement. “This is especially important for postmenopausal women, because cardiovascular risk increases with age and tends to rise after menopause.”

Shahamati and colleagues analyzed data from the Women’s Health Initiative Observational Study (WHI-OS), a prospective cohort of postmenopausal women in the US. Among the women in this program, the team enrolled those with complete baseline dietary data and follow-up information through February 2025. Patients with known cardiovascular disease at baseline, implausible total energy intake, or missing dietary data or follow-up time, were excluded.

The team utilized mean Planetary Health Diet Index (PHDI) as the main exposure, which was calculated via dietary intake reported on the WHI food frequency questionnaire. The team examined PHDI as both quintiles and a continuous score. These data were used to represent each patient’s alignment with the EAT-

 dietary recommendations. The study’s primary outcome was incident total cardiovascular disease, defined as the first occurrence of CHD, stroke, or HF. Secondary outcomes included CHD, stroke, ischemic stroke, hemorrhagic stroke, and HF.

A total of 66,892 postmenopausal women were included in the analytic sample. Baseline PHDI scores ranged from 35-123 (mean +/- SD [standard deviation]; 75.5 +/- 10.3). Mean PHDI scores increased across all quintiles, from roughly 61 in Q1 to 90 in Q5.

How the Diet Changed Cardiovascular Outcomes

Over a median of 19.6 years (interquartile range [IQR], 8.9-26.8), 5033 incident total cardiovascular disease events occurred. Crude incidence rates decreased across all PHDI quintiles for most outcomes; after adjusting for covariates, Shahamati and colleagues found that higher PHDI scores were associated with lower hazards of most cardiovascular disease outcomes. Total cardiovascular disease saw lower hazards from Q2 through Q5 compared with Q1 (Q2 HR, 0.86; 95% CI, 0.78-0.95; Q5 HR, 0.72; 95% CI, 0.64-0.81; 

-trend <.001). This pattern remained consistent for CHD, stroke, ischemic stroke, and HF. For each 10-point higher PHDI score, the hazard was lower for total cardiovascular disease, CHD, stroke, ischemic stroke, and HF. The team did not find a statistically significant association with hemorrhagic stroke.

Ultimately, Shahamati and colleagues determined that women in the highest PHDI quintile had a 28% lower hazard of total cardiovascular disease versus those in the lowest quintile over long-term follow-up. The team noted that these findings are generally consistent with prior longitudinal cohort studies, which found inverse associations between PHDI scores and cardiovascular disease outcomes in other populations.

“Moving to a more plant-forward, higher-quality diet can be accomplished through small, realistic changes,” Shahamati said in a statement. “These changes might include filling half the plate with vegetables more often; using avocado or olive oil in place of butter; choosing oatmeal or whole-grain cereal for breakfast; or trying a meatless meal once per week.”

American Society for Nutrition. Plant-forward planetary health diet linked to lower heart disease risk. 

https://www.eurekalert.org/news-releases/1136409

Roeder A. Planetary Health Diet: Better for you, better for the planet. 

. September 12, 2024. Accessed July 31, 2026. 

https://hsph.harvard.edu/news/planetary-health-diet-better-for-you-better-for-the-planet/

Shahamati D, Yang B, Liu S, et al. Association between the Planetary Health Diet Index and risk of cardiovascular diseases in postmenopausal women: Findings from the Women’s Health Initiative Observational Study. American Journal of Preventive Cardiology. Published online July 17, 2026:101750. 

Higher adherence to the EAT-Lancet Planetary Health Diet among US postmenopausal women was associated with lower long-term risk of incident cardiovascular disease, including CHD, stroke, ischemic stroke, and heart failure. In the WHI-OS cohort followed for a median of 19.6 years, increasing Planetary Health Diet Index (PHDI) scores showed a graded inverse relationship with major cardiovascular outcomes after multivariable adjustment. The highest PHDI quintile demonstrated a 28% lower hazard of total cardiovascular disease versus the lowest, while no significant association emerged for hemorrhagic stroke.

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Planetary Health Diet Reduces Risk of Cardiovascular Disease, CHD, Stroke, HF

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Pooled FIBRONEER trial data show nerandomilast reduced the risk of death by up to 43% versus placebo, though the analysis was post hoc.

Pulmonary Fibrosis

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Nerandomilast Reduces Mortality Risk in Pulmonary Fibrosis Analysis

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Pranav Garimella, MD, on how nephrologists and cardiologists can apply GLP-1 receptor agonist evidence to CKD treatment decisions.

GLP-1s Move Beyond Diabetes as Core Kidney-Protective Therapy

Trace how oral plaque psoriasis therapy has evolved over time, from PDE4 and TYK2 inhibition to once-daily oral peptides.

Oral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides

New phase 3 data show tapinarof cream (VTAMA) delivered early, consistent efficacy across pediatric and adult age groups with atopic dermatitis.

Age-Stratified Phase 3 Data Support Tapinarof Cream in Pediatric Eczema

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Multidisciplinary Care, Evidence-Based Practice in ILD: John Giacona, PhD

Andrew Mastro, MS, PA-C, is a board-certified PA and guest lecturer at both Rush University and Northwestern University. 

Explore why therapeutic inertia keeps plaque psoriasis patients cycling through topicals instead of escalating to systemic therapy.

Breaking the Topical Cycle in Plaque Psoriasis Management

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial

As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.

Food Allergy

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.

What the ADorable-1 Trial Means for Pediatric Eczema Care

New phase 3 ADorable-1 data show lebrikizumab improved skin clearance in children with moderate-to-severe atopic dermatitis.

Latest News

6 Allergy Headlines You Missed in July 2026

6 Cardiology Headlines You Missed in July 2026

What EASI 75, vIGA-AD Scores Reveal About Tapinarof's Eczema Efficacy

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D

Planetary Health Diet Reduces Risk of Cardiovascular Disease, CHD, Stroke, HF